Johnson & Johnson (NYSE:JNJ) Given New $215.00 Price Target at HSBC

Key Points

• HSBC has increased its price target for Johnson & Johnson from $210.00 to $215.00, suggesting an upside potential of 11.25% from the company's previous close.
• Johnson & Johnson currently has an average rating of "Moderate Buy", with 13 analysts rating it as a Buy and only 8 as a Hold, indicating positive sentiment among multiple analysts.
• The company's stock opened at $193.27, with a twelve-month high of $194.40 and a market capitalization of $465.45 billion.

Johnson & Johnson (NYSE:JNJ - Get Free Report) had its price objective increased by stock analysts at HSBC from $210.00 to $215.00 in a research report issued on Thursday,MarketScreener reports. The brokerage presently has a "buy" rating on the stock. HSBC's target price suggests a potential upside of 11.25% from the company's previous close.

A number of other analysts have also weighed in on JNJ. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Argus set a $210.00 price target on Johnson & Johnson in a report on Wednesday. Royal Bank Of Canada reiterated an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a report on Tuesday, September 16th. Finally, Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a "market perform" rating in a report on Monday, October 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $199.88.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $193.27 on Thursday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock's 50 day moving average price is $180.49 and its 200-day moving average price is $164.86. The company has a market capitalization of $465.45 billion, a PE ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently bought and sold shares of the company. Lifestyle Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 3.4% in the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company's stock valued at $312,000 after purchasing an additional 56 shares in the last quarter. Wynn Capital LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company's stock valued at $2,954,000 after acquiring an additional 57 shares during the period. Defined Financial Planning LLC increased its holdings in shares of Johnson & Johnson by 3.0% in the 3rd quarter. Defined Financial Planning LLC now owns 1,926 shares of the company's stock valued at $365,000 after acquiring an additional 57 shares during the period. W.H. Cornerstone Investments Inc. increased its stake in Johnson & Johnson by 0.7% in the 2nd quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company's stock valued at $1,206,000 after buying an additional 58 shares during the period. Finally, YANKCOM Partnership increased its holdings in shares of Johnson & Johnson by 0.8% in the 2nd quarter. YANKCOM Partnership now owns 7,042 shares of the company's stock valued at $1,076,000 after purchasing an additional 58 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.